ANI Pharma (ANIP) Tops Q4 EPS by 16c, provides guidance

ANI Pharma (NASDAQ: ANIP) reported Q4 EPS of $1.00, $0.16 better than the analyst estimate of $0.84. Revenue for the quarter came in at $131.7 million versus the consensus estimate of $122.21 million.

GUIDANCE:

ANI Pharma sees FY2024 EPS of $4.26-$4.67, versus the consensus of $4.33. ANI Pharma sees FY2024 revenue of $520-542 million, versus the consensus of $506.2 million.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

You May Also Be Interested In

• Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
• Greenbrier Companies (GBX) PT Lowered to $42 at BofA Securities